On this page

CORDRAN

Flurandrenolide · Cream

Prescription NDA TE AT RLD Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
CORDRAN
Generic name
Flurandrenolide
Dosage form
Cream
Route
Topical
Marketing category
NDA · NDA
Labeler
INA Pharmaceutics, Inc
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
2
Packages
2
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Flurandrenolide .5 mg/g 197719 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Cream
Route of administration
Topical
Presentations
4

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
012806
Application type
NDA · New Drug Application
Approval date
October 18, 1965
Sponsor
INA PHARMS
Products on application
4
Submissions recorded
20
Products approved under application 012806.
Product Trade name Form Strength Ingredient Status TE Flags
012806-001 CORDRAN OINTMENT FLURANDRENOLIDE Discontinued AT RLD
012806-002 CORDRAN SP CREAM FLURANDRENOLIDE Discontinued — RLD
012806-003 CORDRAN SP CREAM FLURANDRENOLIDE Discontinued — RLD
012806-004 CORDRAN OINTMENT FLURANDRENOLIDE Discontinued — RLD

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
Yes
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 012806.
Type No. Action Status Date Review
Supplement 37 Manufacturing (CMC) Approved July 23, 2013 Standard
Supplement 36 Manufacturing (CMC) Approved June 12, 2013 Standard
Supplement 35 Manufacturing (CMC) Approved December 14, 2012 Standard
Supplement 32 Manufacturing (CMC) Approved March 25, 2008 N/A
Supplement 28 Manufacturing (CMC) Approved July 17, 2002 Standard
Supplement 27 Manufacturing (CMC) Approved November 6, 1998 Standard
Supplement 26 Manufacturing (CMC) Approved August 30, 1991 Standard
Supplement 25 Manufacturing (CMC) Approved October 2, 1990 Standard
Supplement 24 Manufacturing (CMC) Approved December 18, 1987 Standard
Supplement 23 Manufacturing (CMC) Approved June 3, 1987 Standard
Supplement 22 Labeling Approved November 14, 1986 —
Supplement 21 Labeling Approved October 8, 1982 —
Supplement 20 Labeling Approved August 12, 1980 —
Supplement 19 Manufacturing (CMC) Approved November 26, 1979 Standard
Supplement 16 Labeling Approved July 24, 1978 —
Supplement 17 Labeling Approved June 30, 1978 —
Supplement 15 Manufacturing (CMC) Approved December 14, 1977 Standard
Supplement 13 Manufacturing (CMC) Approved November 11, 1977 Standard
Supplement 14 Labeling Approved February 23, 1977 —
Original application 1 Type 1 - New Molecular Entity Approved October 18, 1965 Standard

Review documents

  • 0 · Supplement · July 30, 2013
  • 0 · Supplement · June 14, 2013
  • 0 · Supplement · July 17, 2002

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250707). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20250707

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Cordran® (flurandrenolide, USP) is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION For moist lesions, a small quantity of the cream should be rubbed gently into the affected areas 2 or 3 times a day. Therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. Cordran® (flurandrenolide, USP) should not be used with occlusive dressings unless directed by a physician. Tight-fitting diapers or plastic pants may constitute occlusive dressings.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Topical corticosteroids are contraindicated in patients with a history of hypersensitivity to any of the components of these preparations.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Itching Irritation Dryness Folliculitis Hypertrichosis Acneform eruptions Hypopigmentation Perioral dermatitis Allergic contact dermatitis The following may occur more frequently with occlusive dressings: Maceration of the skin Secondary infection Skin atrophy Striae Miliaria Postmarketing Adverse Reactions The following adverse reactions have been identified during post approval use of flurandrenolide, USP. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Skin : skin striae, hypersensitivity, skin atrophy, contact dermatitis and skin discoloration.

Description

openFDA Drug Labeling

DESCRIPTION Cordran® (flurandrenolide, USP) is a potent corticosteroid intended for topical use. Flurandrenolide occurs as white to off-white, fluffy, crystalline powder and is odorless. Flurandrenolide is practically insoluble in water and in ether. One gram of flurandrenolide dissolves in 72 mL of alcohol and in 10 mL of chloroform. The molecular weight of flurandrenolide is 436.52. The chemical name of flurandrenolide is Pregn-4-ene-3,20-dione, 6-fluoro-11,21-dihydroxy- 16,17-[(1-methylethylidene)bis (oxy)]-, (6α, 11β, 16α)-; its empirical formula is C 24 H 33 FO 6 . The structure is as follows: Each gram of Cordran® Cream (flurandrenolide Cream, USP) contains 0.5 mg (1.145 μmol; 0.05%) flurandrenolide in an emulsified base composed of cetyl alcohol, citric acid, mineral oil, polyoxyl 40 stearate, propylene glycol, sodium citrate, stearic acid, and purified water. Chemical Structure

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Cordran® Cream is supplied in aluminum tubes as follows: Flurandrenolide Cream, USP 0.05%: 60 g (NDC 74157-180-60) 120 g (NDC 74157-130-07) Keep out of reach of children. Storage Keep tightly closed. Protect from light. Store at 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C (59° to 86°F) [See USP controlled room temperature].

Adverse event reports

Source: openFDA FAERS
329
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: FLURANDRENOLIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
74157-130-07 74157-130 INA Pharmaceutics, Inc 1 TUBE in 1 CARTON (74157-130-07) / 120 g in 1 TUBE July 7, 2025
74157-180-60 74157-180 INA Pharmaceutics, Inc 1 TUBE in 1 CARTON (74157-180-60) / 60 g in 1 TUBE July 7, 2025
74157-130 74157-130 INA Pharmaceutics, Inc — July 7, 2025
74157-180 74157-180 INA Pharmaceutics, Inc — July 7, 2025

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 11 sections on this page.